A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

被引：0
|
作者：
Saleh, MN
Gutheil, J
Moore, M
Bunch, PW
Butler, J
Kunkel, L
Grillo-López, AJ
LoBuglio, AF
机构：
[1] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[2] Genentech Inc, S San Francisco, CA 94080 USA
[3] Georgia Canc Specialists, Atlanta, GA USA
[4] Sidney Kimmel Canc Ctr, San Diego, CA USA
[5] IDEC Pharmaceut Corp, San Diego, CA USA
来源：
SEMINARS IN ONCOLOGY | 2000年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：99 / 103
页数：5
相关论文
共 50 条
  • [21] Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): Five cases
    Antonucci, Angela
    Negosanti, Massimino
    Tabanelli, Michela
    Varotti, Claudio
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (03) : 178 - 183
  • [22] Single dose of Anti-CD20 monoclonal antibody (rituximab) treatment in adults with refractory immune thrombocytopenic purpura (ITP).
    Tanaka, Eri
    Hayashi, Shuji
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    BLOOD, 2006, 108 (11) : 321A - 321A
  • [23] Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-cd20 monoclonal antibody rituximab
    Swords, R
    Nolan, A
    Fay, M
    Quinn, J
    O'Donnell, R
    Murphy, PT
    CLINICAL AND LABORATORY HAEMATOLOGY, 2006, 28 (01): : 57 - 59
  • [24] Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (Rituximab)
    Kong, HH
    Prose, NS
    Ware, RE
    Hall, RP
    PEDIATRIC DERMATOLOGY, 2005, 22 (05) : 461 - 464
  • [25] A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia
    El-Najjar, I
    Rule, SAJ
    Nokes, TJC
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 79 - 80
  • [26] Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders
    Trapè, G
    Fianchi, L
    Lai, M
    Laurenti, L
    Piscitelli, R
    Leone, G
    Pagano, L
    HAEMATOLOGICA, 2003, 88 (02) : 223 - 225
  • [27] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    Coiffier, B
    Haioun, C
    Ketterer, N
    Engert, A
    Tilly, H
    Ma, D
    Johnson, P
    Lister, A
    Feuring-Buske, M
    Radford, JA
    Capdeville, R
    Diehl, V
    Reyes, F
    BLOOD, 1998, 92 (06) : 1927 - 1932
  • [28] Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
    Delgado, J
    Bustos, JG
    Jimenez-Yuste, V
    Garcia, B
    de Paz, R
    Gracia, J
    Villar, A
    Quintana, M
    Hernandez-Navarro, F
    BLOOD, 2001, 98 (11) : 59B - 59B
  • [29] Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease
    Papadakis, KA
    Rosenbloom, B
    Targan, SR
    GASTROENTEROLOGY, 2003, 124 (02) : 583 - 583
  • [30] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Mitchell R Smith
    Oncogene, 2003, 22 : 7359 - 7368
12345